Gilead to acquire Tubulis for up to $5 billion to strengthen its oncology portfolio

The acquisition complements Gilead’s existing oncology expertise and development infrastructure

Bristol Myers Squibb showcases transformative advances across oncology portfolio at ESMO 2025

Pfizer completes licensing agreement with 3SBio to expand oncology portfolio

3SBio will receive a payment of $1.25 billion. Pfizer will also make a $100 million equity investment in 3SBio

Pfizer highlights diverse oncology portfolio and combination approaches at ESMO 2024

More than 10 oral and mini-oral presentations span Pfizer’s extensive Oncology portfolio of approved and investigational therapies

Merck to present new data of oncology portfolio at ESMO 2022

Longer-term survival results underscoring role of KEYTRUDA (pembrolizumab) in multiple cancer types, including advanced nonsquamous non-small cell lung cancer (KEYNOTE-189)

Alembic Pharma receives USFDA tentative approval for Binimetinib tablets

Company becomes sole first applicant for 45 mg strength, positioning itself for potential 180-day generic exclusivity in the US market

Dr Reddy’s launches first-to-market generic Bosutinib in US oncology push

Dr Reddy’s has partnered with MSN Laboratories Private Limited on the product, with Dr Reddy’s holding exclusive US marketing rights while MSN leads development and manufacturing

Lilly brings heavy oncology firepower to ASCO with plenary data across cancers

The company is also highlighting early-stage innovation in antibody-drug conjugates and in vivo CAR-T therapy

Emcure crosses US$1 billion revenue milestone in FY26; PAT rises 33%

Pharma major reports FY26 revenue of Rs 9,204 crore with 16.6% growth

AbbVie bets $1.4B on North Carolina pharma mega-campus

Once complete, the site will serve as AbbVie’s U.S. center of excellence for SVP manufacturing